Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Pediatric Blood & Cancer
|
January 26, 2020
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement
Haneen Shalabi, Constance M Yuan, Amita Kulshreshtha, et al.
Nature Communications
|
July 28, 2016
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby, Sang M Nguyen, Thomas J Fountaine, et al.
Haematologica
|
October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
Alan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Lancet (London, England)
|
October 17, 2014
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, et al.
Blood Advances
|
July 14, 2022
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Emily M Hsieh, Regina M Myers, Bonnie Yates, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Nature Medicine
|
November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Robbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Blood Advances
|
April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Adam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Pediatric Blood & Cancer
|
January 26, 2020
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement
Haneen Shalabi, Constance M Yuan, Amita Kulshreshtha, et al.
Nature Communications
|
July 28, 2016
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby, Sang M Nguyen, Thomas J Fountaine, et al.
Haematologica
|
October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
Alan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Lancet (London, England)
|
October 17, 2014
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N Kochenderfer, Maryalice Stetler-Stevenson, et al.
Blood Advances
|
July 14, 2022
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy
Emily M Hsieh, Regina M Myers, Bonnie Yates, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Nature Medicine
|
November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Robbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Blood Advances
|
April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Adam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Page
of 6